Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AA V virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
June 21, 2022
Assignee:
4D Molecular Therapeutics Inc.
Inventors:
David H. Kirn, Melissa Kotterman, David Schaffer
Abstract: Provided is a method for producing myocardial cells from pluripotent stem cells. The myocardial cell production method provided by the present invention includes supplying an artificially produced synthetic peptide to a cell culture that contains pluripotent stem cells. The synthetic peptide is a peptide that contains a myocardial cell differentiation-inducing peptide sequence that induces pluripotent stem cells into myocardial cells. The myocardial cell differentiation-inducing peptide sequence is an amino acid sequence selected from the group consisting of (i) an amino acid sequence constituting the signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence according to (i), and (iii) a modified amino acid sequence from the amino acid sequence according to (i) or (ii).
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
June 14, 2022
Assignees:
Toagosei Co., Ltd., Kyoto University
Inventors:
Tetsuhiko Yoshida, Kenichi Tanaka, Nahoko Baileykobayashi, Yoshinori Yoshida
Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.
Type:
Grant
Filed:
November 18, 2015
Date of Patent:
May 10, 2022
Assignee:
International Stem Cell Corporation
Inventors:
Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
Type:
Grant
Filed:
October 31, 2018
Date of Patent:
May 10, 2022
Assignees:
LONZA BIOLOGICS PLC, PFIZER INC.
Inventors:
James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
Abstract: Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
May 3, 2022
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Aris N. Economides, Andrew J. Murphy, Peter Matthew Lengyel, Peter H. A. Yang
Abstract: Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.
Abstract: Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Type:
Grant
Filed:
December 21, 2015
Date of Patent:
April 19, 2022
Assignee:
Genzyme Corporation
Inventors:
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Abstract: Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and in HSC transplantation, for example allowing this to occur without radiation or chemotherapy conditioning as is typically done in non-myeloablative HSC transplant. In some examples, gene editing methods are used to delete one copy of the CXCR4 gene before HSC or bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.
Type:
Grant
Filed:
July 17, 2015
Date of Patent:
March 22, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Jiliang Gao, Philip M. Murphy, David H. McDermott, Marie Siwicki, Harry L. Malech, Joy Liu, Paejonette Jacobs
Abstract: This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.
Type:
Grant
Filed:
September 1, 2016
Date of Patent:
March 22, 2022
Assignee:
DENOVO BIOPHARMA LLC
Inventors:
Douglas J. Jolly, Amy H. Lin, Andrew Hofacre, Daniel J. Hogan, Derek G. Ostertag
Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
March 22, 2022
Assignee:
Oxford BioMedica (UK) Ltd.
Inventors:
Kyriacos A. Mitrophanous, Scott Ralph, Hannah Stewart, Alan John Kingsman
Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
Abstract: Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
March 8, 2022
Assignees:
Washington State University, Baker Heart and Diabetes Institute
Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
March 8, 2022
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
March 1, 2022
Inventors:
Mari Dezawa, Yoshinori Fujiyoshi, Youichi Nabeshima
Abstract: The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.
Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
February 1, 2022
Assignee:
The Regents of the University of California
Inventors:
David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1? (SDF-1?); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1?. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1? or a polynucleotide codes a protein thereof.
Type:
Grant
Filed:
September 25, 2015
Date of Patent:
January 11, 2022
Assignee:
Helixmith Co., Ltd.
Inventors:
Jae-Gyun Jeong, Jung Hun Lee, Nayeon Lee
Abstract: The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome.